# FY3/2019 Supplementary Material

## 1.Financial Highlights

	2015/3	2016/3	2017/3	2018/3	2019/3
Net sales (Millions of yen)	181,844	219,239	223,468	241,274	245,687
YoY growth rate	10.0%	20.6%	1.9%	8.0%	1.8%
Operating profit (Millions of yen)	6,647	10,489	8,519	10,587	6,733
Operating margin	3.7%	4.8%	3.8%	4.4%	2.7%
Profit attributable to owners of parent (Millions of yen)	2,778	6,329	4,638	6,104	3,790
Return on sales	1.5%	2.9%	2.1%	2.5%	1.5%
Shareholder's equity (Millions of yen)	17,635	32,473	36,447	41,504	41,068
Equity ratio	13.6%	20.6%	20.4%	22.2%	23.0%

#### 2. Financial Indicators

2.2% 16.6%	4.4%	2.8%	2.20/	0.40/
16.6%		2.070	3.3%	2.1%
10.070	25.3%	13.5%	15.7%	9.2%
194.48	432.85	290.03	381.69	243.47
1,257.59	2,030.22	2,278.70	2,595.00	2,739.04
35.00	45.00	50.00	50.00	50.00
8,012,000	16,024,000	16,024,000	16,024,000	16,024,000
18.0%	10.4%	17.2%	13.1%	20.5%
3,055	4,025	3,785	3,350	3,750
48,953	64,496	60,650	53,680	60,090
2.43	1.98	1.66	1.29	1.37
15.71	9.30	13.05	8.78	15.40
10,923	15,615	14,237	17,127	14,525
9.5	6.5	9.0	6.6	7.7
4,026	4,163	4,600	4,876	5,110
47,049	53,544	51,002	50,923	49,206
	194.48 1,257.59 35.00 8,012,000 18.0% 3,055 48,953 2.43 15.71 10,923 9.5 4,026	194.48 432.85 1,257.59 2,030.22 35.00 45.00 8,012,000 16,024,000 18.0% 10.4% 3,055 4,025 48,953 64,496 2.43 1.98 15.71 9.30 10,923 15,615 9.5 6.5 4,026 4,163 47,049 53,544	194.48       432.85       290.03         1,257.59       2,030.22       2,278.70         35.00       45.00       50.00         8,012,000       16,024,000       16,024,000         18.0%       10.4%       17.2%         3,055       4,025       3,785         48,953       64,496       60,650         2.43       1.98       1.66         15.71       9.30       13.05         10,923       15,615       14,237         9.5       6.5       9.0         4,026       4,163       4,600         47,049       53,544       51,002	194.48       432.85       290.03       381.69         1,257.59       2,030.22       2,278.70       2,595.00         35.00       45.00       50.00       50.00         8,012,000       16,024,000       16,024,000       16,024,000         18.0%       10.4%       17.2%       13.1%         3,055       4,025       3,785       3,350         48,953       64,496       60,650       53,680         2.43       1.98       1.66       1.29         15.71       9.30       13.05       8.78         10,923       15,615       14,237       17,127         9.5       6.5       9.0       6.6         4,026       4,163       4,600       4,876         47,049       53,544       51,002       50,923

Return on assets=Profit attributable to owners of parent/Total assets (During the period average)

Return on equity=Profit attributable to owners of parent/Shareholder's equity (During the period average)

Note1: Nihon Chouzai conducted a 2-for-1 stock split effective on Oct.1,2015. Per-share figures for FY3/2013 to FY3/2015 is adjyusted to reflect the stock split.

Note2 : EBITDA=Operating profit/loss+Depreciation+Amortization of goodwill EV=Market cap at the end of each period+Net interest-bearing debt

Note3: Including part-time employees and others(yearly average number of persons employed based on 8-hour conversion)

#### 3. Dispensing Pharmacy Business

	2015/3	2016/3	2017/3	2018/3	2019/3
No.of pharmacies opened	29	27	42	36	32
Including M&A	1	5	21	13	6
No.of pharmacies at the end of each period	511	527	557	585	598
Net sales of dispenshing pharmacy business (Millions of yen)	157,999	190,874	189,327	205,192	208,622
Sales per Pharmacy (Millions of yen)	314	367	349	359	352
No.of prescription (thousands)	11,695	12,301	12,949	13,739	14,192
Unit prices of prescription (yen)	13,330	15,297	14,382	14,739	14,458

#### 4. Consolidated Balance Sheet

Total assets

(Millions of yen) (As of fiscal year-end) 2014/3 2015/3 2016/3 2017/3 2018/3 2019/3 Assets Current assets Cash and deposits 15,429 13,952 32,385 21,200 28,464 29,749 Notes receivable-trade 1,270 321 197 73 213 134 Accounts receivable-trade 17,395 20,001 25,839 26,698 19,902 16,249 Electronically recorded monetary claims-operating 1,091 774 872 1,115 1,465 Merchandise and finished goods 12,165 15,911 15,328 21,455 20,873 22,272 Work in process 751 1,377 1,993 2,509 1,304 1,173 Raw materials and supplies 3,480 3,778 4,695 5,550 6,047 6,020 Deferred tax assets 1,233 1,138 1,447 1,262 1,508 Other 1.655 2,534 2,187 2,713 3,698 3,071 Allowance for doubtful accounts (10)(8) (10)(7) (6) (5)Total current assets 53,373 60.096 82.327 80.132 84.838 83.121 Non-current assets Property, plant and equipment Buildings and structures 26,103 32,136 36,733 39,675 53,483 52,956 Accumulated depreciation (12,113)(13,487)(15, 196)(17,372)(19,064)(20,582)Buildings and structures, net 13,990 18,648 21,537 22,303 34,418 32,374 Machinery, equipment and vehicles 14,129 3,725 6,405 7,862 12,690 19,246 Accumulated depreciation (1.189)(1,531)(2,007)(2,649)(3,543)(4,539)Machinery, equipment and vehicles, net 4,874 2,536 10,585 14.707 5,855 10,040 Land 15,318 17,043 17,188 18,016 19,357 16,961 Leased assets 1,438 1,724 2,943 2,995 2,888 2,943 Accumulated depreciation (654)(1,582)(2,094)(871)(1,233)(1,858)Leased assets, net 784 1,710 794 853 1,413 1,084 Construction in progress 7,076 4,798 2,807 13,521 6,750 1,133 Other 9,293 10,394 11,765 13,564 16,399 14,816 Accumulated depreciation (6.876)(7,792)(8,867)(10,346)(11,352)(12,564)Other, net 2,417 2,601 2,898 3,217 3,464 3,835 Total property, plant and equipment 42,123 48,819 51,997 68,513 75,662 69,806 Intangible assets Goodwill 9.265 8.661 8.507 14.605 15.418 14,552 Other 1,838 1.714 1,615 2,167 2,534 2,353 Total intangible assets 11,103 10,376 10,122 16,773 17,952 16,906 Investments and other assets Investment securities 1,030 1,153 945 1,039 20 17 Long-term loans receivable 979 886 738 687 975 817 Lease and guarantee deposits 6,934 6,990 6,932 7,072 7,049 7,357 Deferred tax assets 660 495 647 587 786 2,610 Other 1,089 1,233 1,239 1,216 1,242 1,160 Total investments and other assets 10,694 10,848 10,650 10,733 9,837 11,833 Total non-current assets 63,921 70,044 72,770 96,019 103,452 98,545

117,295

130,141

157,609

178,347

186,573

Note: The amounts for the previous fiscal years in this materials do not reflect the revisions of the accounting standards.

178,677

Current liabilities Accounts payable-trade 26,861 31.306 41.989 38.909 36.203 37.274 Notes payable-trade 2,102 Electronically recorded obligations-operating 2,086 2,664 2,124 3,770 3,081 Short-term loans payable 7,750 5,100 7,000 7,000 Current portion of bonds 3,889 5,963 15,309 Current portion of long-term loans payable 6,069 13,411 16,143 Lease obligations 263 421 400 390 311 261 Income taxes payable 1,507 1,478 1,625 2,745 1,537 3,040 Provision for bonuses 1,793 2.080 2,249 2,547 2,775 3,023 Provision for directors' bonuses 74 98 138 117 137 86 Provision for sales rebates 102 130 Asset retirement obligations 4 9 4 10 4,316 5,826 7,257 8.759 7,739 4,546 Total current liabilities 55,666 53,474 68,985 66,305 70,310 69,100 Non-current liabilities Long-term loans payable 35,165 50.621 46.184 70.678 68.372 62,470 Bonds payable 7,000 7,000

1,648

1,471

886

917

682

240

(213)

59,031

1,337

1,040

1,157

957

723

312

(231)

56,151

2015/3

2016/3

2017/3

1,002

609

949

760

298

(161)

75,595

1,294

697

1,991

1,048

1,503

821

320

(144)

74,756

436

1,349

1,093

1,695

1,145

68,504

313

0

(127)

(127)

41,073

178,677

Total liabilities 101,446 112.505 125.136 141.900 145.066 137,604 Net assets Shareholders' equity Capital stock 3,953 3,953 3,953 3,953 3,953 3,953 Capital surplus 4,754 4,754 10,926 10,926 10,926 10,926

968

907

915

659

162

45,779

Retained earnings 9,310 21,511 11,868 17,672 26,816 29,815 (3,498)Treasury shares (2,171)(3,059)(44)(46)(47)Total shareholders' equity 15,845 17,515 32,507 36,345 41,648 41,196 Accumulated other comprehensive income Valuation difference on available-for-sale securities 237 333 196 263 0

(234)

Total accumulated other comprehensive income 3 119 101 (34)(144)Non-contorolling interest Total net assets 15,849 17,635 32,473 36,447 41,506 Total liabilities and net assets 117,295 130,141 157,609 178,347 186,573

Note: The amounts for the previous fiscal years in this materials do not reflect the revisions of the accounting standards.

(As of fiscal year-end)

Liabilities

Other

Other

Lease obligations

Net defined benefit liability

Asset retirement obligations

Total non-current liabilities

Long-term accounts payable-installment purchase

Provision for directors' retirement benefits

Remeasurements of defined benefit plans

2014/3

(Millions of yen)

2019/3

2018/3

#### 5. Consolidated Statement of Income

(Millions of yen)

(Fiscal years ended)	2014/3	2015/3	2016/3	2017/3	2018/3	2019/3
Net sales	165,347	181,844	219,239	223,468	241,274	245,687
Cost of sales	139,723	149,915	180,171	184,210	197,437	203,711
Gross profit	25,623	31,929	39,068	39,258	43,837	41,975
Selling, general and administrative expenses	20,878	25,281	28,578	30,738	33,250	35,242
Operating profit	4,744	6,647	10,489	8,519	10,587	6,733
Non-operating income	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	-,	,	-,	,	-,
Interest income	2	3	6	1	0	0
Commission fee	116	122	137	144	151	50
Rent income	147	338	378	404	436	430
Compensation income	46	42	_	_	_	_
Insurance return	_	_	_	75	_	_
Other	194	186	217	157	193	178
Total non-operating income	508	693	740	783	781	659
Non-operating expenses						
Interest expenses	718	811	790	687	635	525
Commission fee	79	30	45	37	44	13
Rent expenses	_	243	294	322	328	355
Loss on retirement of non-current assets	36	55	35	113	45	221
Other	229	197	185	164	175	198
Total non-operating expenses	1,064	1,337	1,351	1,326	1,230	1,315
Ordinary profit	4,188	6,003	9,878	7,976	10,138	6,077
Extraordinary income	,	,	,	,	,	,
Gain on sales of non-current assets	20	5	22	28	0	231
Gain on sales of investment securities	1	_	_	0	360	8
Gain on transfer of business	_	_	_	_	48	1,092
Total extraordinary income	22	5	22	28	408	1,332
Extraordinary losses						•
Loss on sales of non-current assets	4	_	_	6	10	24
Impairment loss	230	239	219	171	491	607
Retirement benefit expenses	_	238	_	_	_	_
Loss on sales of investment securities	0	_	_	_	_	_
Total extraordinary losses	235	477	219	177	501	632
Profit before income taxes	3,975	5,531	9,681	7,827	10,045	6,777
Income taxes-current	2,147	2,705	3,720	3,024	4,272	3,308
Income taxes-deferred	(41)	47	(368)	164	(331)	(324)
Total income taxes	2,105	2,752	3,352	3,188	3,940	2,984
Profit note	1,870	2,778	6,329	4,638	6,104	3,792
Profit (loss) attributable to non-controlling interests note	(31)	· —	· —	_	·	2
Profit attributable to owners of parent note	1,901	2,778	6,329	4,638	6,104	3,790

Profit attributable to owners of parent note 1,901 2,778 6,329

Note: Accompanying the revision of Accounting Standards for Business Combinations, etc., the names of items presented have been changed.

The rivised standards have been applied from the fiscal year ended March 31,2016.

### 6. Consolidated Statement of Cash Flows

(Fiscal years ended)	2014/3	2015/3	2016/3	2017/3	2018/3	ions of yen) 2019/3
Consolidated Statement of Cash Flows	2011/0	2010/0	2010/0	201170	2010/0	2010/0
Profit before income taxes	3,975	5,531	9,681	7,827	10,045	6,777
Depreciation	3,825	3,631	4,461	4,741	5,214	6,304
Amortization of long-term prepaid expenses	107	106	107	104	126	160
Impairment loss	230	239	219	171	491	607
Amortization of goodwill	559	644	663	976	1,326	1,487
Increase (decrease) in allowance for doubtful accounts	0	1	(0)	(9)	(3)	(0)
Increase (decrease) in provision for bonuses	173	286	167	279	225	245
Increase (decrease) in provision for allowance for sales discount	(141)	28	(130)			
Increase (decrease) in provision for directors' bonuses	57	23	40	(21)	20	(50)
Increase (decrease) in net defined benefit liability	177	490	223	118	202	188
Increase (decrease) in provision for directors' retirement benefits	(295)	(21)	70	(7)	98	45
Interest and dividend income	(24)	(24)	(27)	(22)	(21)	(2)
Interest expenses	718	811	790	687	635	525
Loss (gain) on sales of non-current assets	(20)	(5)	(22)	(22)	10	(206)
Loss (gain) on sales of investment securities	(20)	(5)	(22)	Δ0	(360)	(8)
Loss on abolishment of retirement benefit plan	_		_	<u> </u>	(48)	(1,092)
Decrease (increase) in notes and accounts receivable-trade	(1,942)	(2,748)	(5,339)	(46)	6,691	3,485
Decrease (increase) in inventories	523	(4,545)	(881)	(7,005)	1,442	(1,314)
Increase (decrease) in notes and accounts payable-trade	241	4,422	11,212			342
Decrease (increase) in prepaid expenses	(50)	(85)		(4,135) (84)	(1,399) (111)	(74)
Increase (decrease) in accrued expenses	66	219	(7) 265	132	324	, ,
Decrease (increase) in accounts receivable - other	00	219	200	132	324	(82)
	— 768	(5.47)	052	750	200	998
Increase (decrease) in accounts payable-other Other, net	766 167	(547)	853	758	390	(791)
Subtotal		761	441	(349)	1,198	1,460
Interest and dividend income received	9,119	9,220	22,787	4,093	26,500	19,004
	(720)	24	27	22	21	(505)
Interest expenses paid	(728)	(822)	(792)	(702)	(623)	(525)
Income taxes paid	(2,171)	(2,591)	(2,695)	(4,354)	(2,756)	(4,908)
Net cash provided by (used in) operating activities	6,243	5,831	19,327	(940)	23,141	13,572
Cash flows from investing activities			(5)			
Payments into time deposits	_	-	(5)	_	_	_
Proceeds from withdrawal of time deposits	(0.007)	246	82	5		
Purchase of property, plant and equipment	(8,227)	(5,808)	(6,880)	(20,222)	(12,076)	(5,303)
Proceeds from sales of property, plant and equipment	136	8	25	72	46	1,723
Purchase of intangible assets	(247)	(246)	(243)	(926)	(656)	(591)
Proceeds from sales of investment securities	29			2	999	10
Increase in long-term prepaid expenses	(60)	(162)	(104)	(231)	(95)	(123)
Payments for transfer of business	(1,344)	(2,330)	(454)	(1,713)	(585)	(368)
Proceeds from transfer of business		_		_	114	4,093
Purchase of shares of subsidiaries resulting in change in scope of consolidation	(4,588)	_	(226)	(4,899)	(1,126)	(785)
Payments for loans receivable	(157)	(121)	(16)	(443)	(448)	(92)
Collection of loans receivable	122	130	115	103	88	85
Payments for lease and guarantee deposits	(348)	(336)	(256)	(385)	(251)	(699)
Proceeds from collection of lease and guarantee deposits	185	149	160	134	172	281
Other, net	(10)	35	(19)	59	(25)	(0)
Net cash provided by (used in) investing activities	(14,510)	(8,437)	(7,823)	(28,444)	(13,843)	(1,770)

			ye	

1						•		
(Fiscal years ended)	2014/3	2015/3	2016/3	2017/3	2018/3	2019/3		
Cash flows from financing activities								
Net increase (decrease) in short-term loans payable	1,150	(2,650)	(5,100)	(236)	_	_		
Proceeds from long-term loans payable	19,400	17,300	10,400	33,600	13,000	10,625		
Repayments of long-term loans payable	(10,920)	(4,101)	(6,069)	(6,509)	(13,408)	(15,694)		
Redemption of bonds	(185)	(7,000)	_	(7,000)	_	_		
Repayments of lease obligations	(235)	(434)	(430)	(412)	(391)	(311)		
Repayments of installment payables	_	(252)	(431)	(431)	(433)	(893)		
Proceeds from sales of treasury shares	97	85	_	_	_	_		
Proceeds from disposal of treasury shares	_	_	9,194	_	_	_		
Purchase of treasury shares	_	(1,019)	(6)	(1)	(1)	(3,451)		
Cash dividends paid	(506)	(504)	(524)	(802)	(799)	(791)		
Cash dividends paid to minority shareholders	(17)	_	_	_	_			
Net cash provided by (used in) financing activities	8,782	1,422	7,031	18,205	(2,034)	(10,516)		
Net increase (decrease) in cash and cash equivalents	514	(1,183)	18,535	(11,180)	7,264	1,284		
Cash and cash equivalents at beginning of period	14,513	15,027	13,844	32,380	21,200	28,464		
Cash and cash equivalents at end of period	15,027	13,844	32,380	21,200	28,464	29,749		

## 7.Business Segment Performance

	(Millions of							
	2014/3	2015/3	2016/3	2017/3	2018/3	2019/3		
Dispensing pharmacy business								
Net sales	145,957	157,999	190,874	189,327	205,192	208,622		
Segment profit	7,672	7,698	10,707	9,560	12,411	8,707		
Segment assets	69,515	71,103	95,198	94,235	93,088	91,220		
Depreciation	2,175	1,992	2,107	2,154	2,194	2,338		
Amortization of goodwill	506	546	565	878	1,228	1,389		
Impairment loss	230	239	219	171	347	607		
Increase in property, plant and equipment and intangible assets	2,732	3,285	4,046	4,238	4,679	3,215		
Pharmaceutical manufacturing and sales business								
Net sales	23,192	27,550	32,598	36,821	38,066	40,659		
Segment profit	500	1,888	2,668	1,719	1,194	1,885		
Segment assets	40,216	50,666	54,065	75,551	84,465	77,237		
Depreciation	1,109	1,257	2,003	2,222	2,677	3,589		
Amortization of goodwill	52	97	97	97	97	97		
Impairment loss	_	_	_	_	143	_		
Increase in property, plant and equipment and intangible assets	5,672	8,712	3,663	18,742	10,245	1,582		
Medical Professional Staffing and Placement Business								
Net sales	5,046	6,554	8,934	10,500	11,970	13,083		
Segment profit	770	1,266	1,599	1,710	1,842	1,478		
Segment assets	1,246	2,103	2,285	2,335	3,828	4,696		
Depreciation	44	49	39	25	33	51		
Amortization of goodwill	_	_	_	_	_	_		
Impairment loss	_	_	_	_	_	_		
Increase in property, plant and equipment and intangible assets	19	27	30	45	89	291		

# 8.Capital investment $\cdot$ Depreciation $\cdot$ R&D expenses

					(Mil	lions of yen)
	2014/3	2015/3	2016/3	2017/3	2018/3	2019/3
Capital investment	9,069	12,279	8,073	23,344	15,316	5,254
Depreciation	3,825	3,631	4,461	4,741	5,214	6,304
Amortization of long-term prepaid expenses	107	106	107	104	126	160
Amortization of goodwill	559	644	663	976	1,326	1,487
Goodwill balanse	9,265	8,661	8,507	14,605	15,418	14,552
Impairment loss	230	239	219	171	491	607
R&D expenses	1,534	1,767	1,913	2,388	2.784	2,764

#### 9.Company Plofile

Trade Name NIHON CHOUZAI Co.,Ltd.

Established March 1980

Headquarters 37F GranTokyo North Tower,1-9-1, Marunouchi, Chiyoda-Ku,100-6737 Tokyo

Capital 3,953.02 million yen Total Number of Issued Shares 16,024,000 shares

Fiscal Year-end March

Stock Exchange for Listing Tokyo Stock Exchange(TSE) First Section

Securities Code 3341

Our Business Management of health insurance dispensing chain pharmacies,

manufacture and sales of generic drugs,

employment placement and dispatching service of medical professionals,

information provision and consulting

Number of employees(persons)(As of March 31,2019)

5,110 Number of pharmacies(As of March 31,2019) 598

Number of employees: Consolidated, including part-time employees and others (yearly average number of persons employed based on 8-hour conversion)